<DOC>
	<DOCNO>NCT01265823</DOCNO>
	<brief_summary>W11-050 Mexican open label multicenter study design ass safety efficacy adalimumab treatment patient active plaque psoriasis fail prior conventional systemic psoriasis treatment candidate systemic therapy .</brief_summary>
	<brief_title>Immediate Response With Adalimumab Its Impact Quality Life Other Comorbidity Factors Patients With Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description>Up 150 subject diagnosis active plaque psoriasis fulfil study eligibility criterion enrol Mexico . Adalimumab administer follow : 80 mg baseline , follow 40 mg every week ( eow ; start week 1 week 15 ) . The study drug self administer via subcutaneous ( sc ) injection . Safety efficacy measure perform throughout study .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Able willing give write informed consent prior study related procedure comply requirement study protocol 2 . Male female subject 18 75 year old 3 . Diagnosis moderate severe type I II plaque psoriasis ( Type I : symptom onset 40 year old ; Type II : symptom onset 40 year old ) , least 6 month duration 4 . Documented moderate severe plaque psoriasis base Psoriasis Area Severity Index ( PASI ) score &gt; 10 5 . Subjects naïve adalimumab therapy 6 . Subject must evaluate active latent tuberculosis ( TB ) infection use Purified Protein Derivative ( PPD ) skin test , chest xray ( posterior anterior ( PA ) lateral view ) detail review subject 's medical history . This screening must negative 7 . A negative pregnancy test ( serum human chorionic gonadotrophin ) woman childbearing potential prior start study treatment . ( Nonchildbearing potential define postmenopausal least 1 year surgically sterile [ bilateral tubal ligation , bilateral oophorectomy hysterectomy ] ) 8 . Able willing selfadminister subcutaneous injection available suitable person administer subcutaneous injection 9 . Subject judge generally good health determine investigator 1 . Prior treatment investigational agent within 30 day , five halflives product , ever longer . Subject treat investigational drug chemical biologic nature within minimum 30 day five half life ( whichever longer ) drug prior study entry ( Baseline Visit ) 2 . Subject active skin disease skin infection ( bacterial , fungal , viral ) may interfere evaluation psoriasis compromise subject 's safety 3 . Subject history dysplasia , malignancy ( include lymphoma leukemia ) , lymphoproliferative disease : . Successfully completely treat nonmetastatic squamous basal cell carcinoma skin recurrence within last five year . b . Localized carcinoma situ cervix cervical dysplasia , recurrence within last five year 4 . Persistent recurrent infection severe infection require hospitalization treatment intravenous ( IV ) antibiotic , IV antiviral , IV antifungal within 30 day , oral antibiotic , oral antiviral oral antifungal within 14 day prior Baseline Visit 5 . Other medical condition : uncontrolled diabetes , unstable ischemic heart disease , congestive heart failure New York Heart Association ( NYHA ) IIIIV , recent stroke ( within three month ) , chronic leg ulcer condition ( e.g. , indwell urinary catheter ) , opinion investigator , may place subject risk 6 . Previous diagnosis sign highly indicative central nervous system demyelinate disease ( e.g. , optic neuritis , ataxia , apraxia ) 7 . History listeriosis , histoplasmosis , chronic active Hepatitis B infection , human immunodeficiency virus ( HIV ) infection , immunodeficiency syndrome , chronic recur infection active TB 8 . Female subject pregnant breastfeed 9 . History clinically significant drug alcohol abuse last year 10 . Subject start receive new topical therapy within last four week prior Baseline visit area palm , soles foot , axilla groin 11 . Subject start treated ultraviolet B ( UVB ) phototherapy , within last four week prior Baseline visit 12 . Subject treat psoralen ultraviolet A ( PUVA ) phototherapy within last four week prior Baseline visit 13 . Subject initiate new systemic agent within last four week prior Baseline visit 14 . Patients history atopy 15 . Patients autoimmune disease systemic lupus erythematosus ( SLE ) , Sdx Sjögren , vasculitis etc 16 . Known hypersensitivity excipients adalimumab state label 17 . Female subject pregnant breastfeed consider become pregnant study 18 . Subject consider investigator , reason , unsuitable candidate study 19 . Subject prior exposure Tysabri ( natalizumab ) , Orencia ( abatacept ) 20 . Subjects positive immunologic test hepatitis A , B C ( Positive test following : hepatitis A viral antibody immunoglobulin M ( HAVIgM ) , hepatitis B surface antigen ( HBsAg ) hepatitis C virus antibody ( HCV Ab ) 21 . Subjects positive immunologic test HIV determine enzymelinked immunosorbent assay ( ELISA ) method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Humira</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Plaque Psoriasis</keyword>
</DOC>